These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8610267)

  • 1. Adjuvant chemotherapy in the node-negative breast cancer patient.
    Styblo TM; Wood WC
    Surg Clin North Am; 1996 Apr; 76(2):327-41. PubMed ID: 8610267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
    Cole BF; Gelber RD; Gelber S; Coates AS; Goldhirsch A
    Lancet; 2001 Jul; 358(9278):277-86. PubMed ID: 11498214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review).
    Kim R; Osaki A; Toge T
    Int J Oncol; 2001 Nov; 19(5):1075-80. PubMed ID: 11605012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-agent chemotherapy for early breast cancer.
    Early Breast Cancer Trialists' Collaborative Group
    Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
    Dignam JJ; Dukic V; Anderson SJ; Mamounas EP; Wickerham DL; Wolmark N
    Breast Cancer Res Treat; 2009 Aug; 116(3):595-602. PubMed ID: 18830816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen for early breast cancer.
    Early Breast Cancer Trialists' Collaborative Group
    Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.